US False Claims Act Dismissal Motions Are Executive Branch Over-Reach, Whistleblowers Say
Executive Summary
Justice Department lacks absolute right to dismiss meritorious qui tam complaints filed by affiliates of National Healthcare Analysis Group against numerous pharmaceutical companies, whistleblowers say, taking issue with government’s “personal attacks” on their business model and research practices.
You may also be interested in...
Will US Government Pursue Fewer False Claims Act Cases In 2019?
Fallout from Supreme Court's Escobar decision and Department of Justice memos could impact types of healthcare fraud complaints in which the government intervenes.
False Claims Act: US Justice Department Gives Pharma Early Christmas Present
Government seeks dismissal of 10 qui tam complaints related to pharma reimbursement support services, asserting the lawsuits were brought by a ‘professional’ whistleblower and lack merit.
Pharma May See Brighter Enforcement Environment After US Justice Department Policy Changes
Policy revisions on individual liability for corporate misconduct, noncompliance with agency guidance documents and dismissal of False Claims Act cases suggest a greater willingness by DoJ leadership to reconsider arguments often raised by life sciences companies, attorneys say at a Food and Drug Law Institute conference.